☆ 4.7 Meeting Abstract

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

BLOOD (2019)

主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discuss science. Find collaborators. Network.

Join a conversation